References:
1. Rocha e Silva M, Beraldo WT, Rosenfeld G ”Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin”. American Journal of Physiology. 156 (2): 261–73.
2. Almeida, Teresa & Rojo, Javier & Nieto, Pedro & Pinto, Francisco & Hernandez Ferrer, Mariano & Martín et al. Tachykinins and Tachykinin Receptors: Structure and Activity Relationships. Current medicinal chemistry. 11; 2004; 2045-81.
3. Björkqvist J, Sala-Cunill A, Renné T. Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost. 2013;109: 368–74
4. Kaplan AP, Ghebrehiwet B. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol. 2010;47: 2161–9
5. Hall JM. Bradykinin receptors. Gen Pharmacol. 1997(1):1-6.
6. Taub JS, Guo R, Leeb-Lundberg LM, Madden JF, Daaka Y. Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res. 2003 ;63(9):2037-41.
7. Duka A, Duka I, Gao G, Shenouda S, Gavras I, Gavras H. Role of bradykinin B1 and B2 receptors in normal blood pressure regulation. Am J Physiol Endocrinol Metab. 2006; 291: E268–74.
8. Emanueli C, Bonaria Salis M, Stacca T, Pintus G, Kirchmair R, Isner JM, et al. Targeting kinin B (1) receptor for therapeutic neovascularization. Circulation. 2002; 105:360–6
9. Lagneux C, Adam A, Lamontagne D. A study of the mediators involved in the protection induced by exogenous kinins in the isolated rat heart. Int Immunopharmacol. 2003;3: 1511–1518
10. Golias Ch, Charalabopoulos A, Stagikas D, Charalabopoulos K, Batistatou A. The kinin system–bradykinin: biological effects and clinical implications. Multiple role of the kinin system–bradykinin. Hippokratia. 2007 Jul;11(3):124-8.
11. Terzuoli E, Corti F, Nannelli G, Giachetti A, Donnini S, Ziche M. Bradykinin B2 Receptor Contributes to Inflammatory Responses in Human Endothelial Cells by the Transactivation of the Fibroblast Growth Factor Receptor FGFR-1. Int J Mol Sci. 2018 ;19(9):2638.
12. Duchêne J, Schanstra J, Cellier E, Bascands JL, Girolami JP [30 years: Happy birthday, GPCR. The bradykinin B2 receptor: an alternative and antiproliferative pathway]. Nephrologie. 2002; 23(1):39-41.
13. Maggio JE. ”Tachykinins”. Annu. Rev. Neurosci. 1998; 11 : 13–28.
14. Helke CJ, Krause JE, Mantyh PW, Couture R, Bannon MJ. ”Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms”. FASEB J . 1990; 4  (6): 1606–15.
15. Avanov AIa. ”Tachykinins and conformational aspects of their interactions with receptors”. Mol. Biol. (Mosk) . 1992;26  (1): 5–24.
16. Boot JD, de Haas S, Tarasevych S, ”Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma”. Am. J. Respir. Crit. Care Med .2007; 175  (5): 450–7.
17. Dornan WA, Vink KL, Malen P, Short K, Struthers W, Barrett C. ”Site-specific effects of intracerebral injections of three neurokinins (neurokinin A, neurokinin K, and neurokinin gamma) on the expression of male rat sexual behavior”. Physiol. Behav . 1993;54  (2): 249–58.
18. Grady EF, Gamp PD, Jones E, Baluk P, McDonald DM, Payan DG, Bunnett. Endocytosis and recycling of neurokinin 1 receptors in enteric neurons. NW Neuroscience. 1996; 75(4):1239-54.
19. Southwell BR, Seybold VS, Woodman HL, Jenkinson KM, Furness. Quantitation of neurokinin 1 receptor internalization and recycling in guinea-pig myenteric neurons. JB Neuroscience. 1998; 87(4):925-31.
20. Tachykinins and their functions in the gastrointestinal tract. Shimizu Y, Matsuyama H, Shiina T, Takewaki T, Furness JB Cell Mol Life Sci. 2008; 65(2):295-311.
21 . Deiteren A, De Winter BY, Nullens S, Pelckmans PA, De Man JG. Role of tachykinin receptors in the modulation of colonic peristaltic activity in mice. Eur J Pharmacol. 2011; 667(1-3):339-47.
22 . Hernandez J, Lackner A, Aye P, Mukherjee K, Tweardy DJ, Mastrangelo MA, Weinstock J, Griffiths J, D’Souza M, Dixit S, Robinson P. Substance P is responsible for physiological alterations such as increased chloride ion secretion and glucose malabsorption in cryptosporidiosis. Infect Immun. 2007; 75(3):1137-43.
23. The role of substance P, hemokinin and their receptor in governing mucosal inflammation and granulomatous responses. Weinstock JV Front Biosci. 2004; 9():1936-43.
24. Jerde TJ, Saban R, Bjorling DE, Nakada SY. NK-2 is the predominant tachykinin receptor subtype in the swine ureter. BJU Int. 1999; 83(3):312-8.
25. Pinto FM, Ravina CG, Subiran N, Cejudo-Román A, Fernández-Sánchez M, Irazusta J et al. Autocrine regulation of human sperm motility by tachykinins. Reprod Biol Endocrinol. 2010; 8:104.
26. Song IS, Bunnett NW, Olerud JE, Harten B, Steinhoff M, Brown JR et al. Substance P induction of murine keratinocyte PAM 212 interleukin 1 production is mediated by the neurokinin 2 receptor (NK-2R). Exp Dermatol. 2000; 9(1):42-52.
27. Madeddu P, Varoni MV, Palomba D, Emanueli C, Demontis MP, Glorioso N et al. Cardiovascular phenotype of a mouse strain with disruption of the bradykinin B2-receptor gene. Circulation . 1997; 96:3570–8.
28. DomBourian, M. G. Turner, N. A. Gerovac, T. A. Vemuganti, R. Miranpuri, G. S. Türeyen et al. B1 and TRPV-1 receptor genes and their relationship to hyperalgesia following spinal cord injury. Spine. Phila. Pa. 1976. 2006; 31: 2778–282;
29. Tang Z, Wang Z, Hu Z, Zhang M, Li L, Li B. The role of bradykinin in lung ischemia-reperfusion injury in a rat lung transplantation model. Acta Cir Bras. 2016;(12):807-812.
30. Bas, M., V. Adams, T. Suvorava, T. Niehues, T. K. Hoffmann, and G. Kojda. “Nonallergic Angioedema: Role of Bradykinin.” Allergy 62, 2007; (8): 842–56.
31. Roper M, Ham RG, Stewart JM. Biosynthesis of substance P in cultured mouse neuroblastoma and rat glioma cells. Harkins J, Brain Res. 1978; 147(2):405-9.
32. Akazawa T, Kwatra SG, Goldsmith LE, Richardson MD, Cox EA, Sampson JH, Kwatra MM. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.J Neurochem. 2009 (4):1079-86.
33. Rosso M, Robles-Frías MJ, Coveñas R, Salinas-Martín MV, Muñoz M. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumour Biol. 2008; (4):245-54.
34. Kradin R, MacLean J, Duckett S, Schneeberger EE, Waeber C, Pulmonary response to inhaled antigen: neuroimmune interactions promote the recruitment of dendritic cells to the lung and the cellular immune response to inhaled antigen. Pinto C Am J Pathol. 1997(5):1735-43.
35. Augustyniak D, Jankowski A, Mackiewicz P, Skowyra A, Gutowicz J, Drulis-Kawa Z. Innate immune properties of selected human neuropeptides against Moraxella catarrhalis and non-typeable Haemophilus influenzae. BMC Immunol. 2012; (13):24.
36. Okaya T, Holthaus R, Kato A, Lentsch AB, Involvement of the neuropeptide substance P in lung inflammation induced by hepatic ischemia/reperfusion. Inflamm Res. 2004;(6):257-61.
37. Rogers DF. Motor control of airway goblet cells and glands. Respir Physiol. 2001 Mar; 125(1-2):129-44.
38. Horn CC, Wallisch WJ, Homanics GE, Williams JP. Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting. Eur J Pharmacol. 2014; (722): 55-66.
39. Kakoki M, Smithies O. The kallikrein kinin system in health and in diseases of the kidney. Kidney Int. 2009, (75), 1019–30.
40. Merrifield, R.B. Solid-Phase Peptide Synthesis. III. An Improved Synthesis of Bradykinin. Biochemistry 1964; (3), 1385–90.
41. Marceau, F; Bawolak, M.T.; Fortin, J.P.; Morissette, G.; Roy, C.; Bachelard, H et al. Bifunctional ligands of the bradykinin B 2 and B 1 receptors: An exercise in peptide hormone plasticity. Peptides 2018, (105), 37–50.
42. Cicardi, M.; Banerji, A.; Bracho, F.; Malbrán, A.; Rosenkranz, B.; Riedl, M et al. Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema. N. Engl. J. Med. 2010, (363), 532–41.
43. Shakur, H.; Andrews, P.; Asser, T.; Balica, L.; Boeriu, C.; Quintero, J.D.C et al. The BRAIN TRIAL: A randomised, placebo-controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury. Trials 2009, (10), 1–10.
44. Tenti, S.; Pascarelli, N.A.; Cheleschi, S.; Guidelli, G.M.; Fioravanti, A. The Emerging Role of Bradykinin in the Pathogenesis of Osteoarthritis and its Possible Clinical Implications. Curr. Rheumatol. Rev. 2016, (12), 177–84
45. Balaguer, J.M.; Yu, C.; Byrne, J.G.; Ball, S.K.; Petracek, M.R.; Brown, N.J et al. Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: A randomized clinical trial. Clin. Pharmacol. Ther. 2013, (93), 326–34.
46. Straka, B.T.; Ramirez, C.E.; Byrd, J.B.; Stone, E.; Woodard-Grice, A.; Nian, H. et al. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. J. Allergy Clin. Immunol. 2017, (140), 242–8.
47. Pedersen, C.M.; Schmidt, M.R.; Barnes, G.; Bøtker, H.E.; Kharbanda, R.K.; Newby, D.E et al. Bradykinin does not mediate remote ischaemic preconditioning or ischaemia-reperfusion injury in vivo in man. Heart 2011, (97), 1857–61.
48. Whalley, E.T.; Figueroa, C.D.; Gera, L.; Bhoola, K.D. Discovery and therapeutic potential of kinin receptor antagonists. Expert Opin. Drug Discov. 2012, (7), 1129–48.
49. Warren, K.; Jakacki, R.; Widemann, B.; Aikin, A.; Libucha, M.; Packer, R et al. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: A report from the Children’s Oncology Group. Cancer Chemother. Pharmacol. 2006, (58), 343–7.
50. Da Costa, P.L.N.; Sirois, P.; Tannock, I.F.; Chammas, R. The role of kinin receptors in cancer and therapeutic opportunities. Cancer Lett. 2014, (345), 27–38.
51. Pruneau, D.; Bélichard, P.; Sahel, J.A.; Combal, J.P. Targeting the kallikrein-kinin system as a new therapeutic approach to diabetic retinopathy. Curr. Opin. Investig. Drugs 2010, (11), 507–14.
52. Bozó, É.; Éles, J.; Keser, G.M. Bradykinin B1 receptor antagonists: A patent update 2009–2012. Expert Opin. Ther. Pat. 2012, (22), 1443–52.
53. Quartara L.; Altamura, M. (August 2006), ”Tachykinin receptors antagonists: From research to clinic”, Current Drug Targets, 7 (8): 975–992,
54. Lohr L (2008). ”Chemotherapy-induced nausea and vomiting”. Cancer Journal. 14 (2): 85–93.
55. ”FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy” Food and Drug Administration. October 10, 2014. Archived from  the original on February 1, 2017 . Retrieved march 17,2022.
56. Duffy RA, Morgan C, Naylor R, Higgins GA, Varty GB, Lachowicz JE et al. ”Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets”. Pharmacology, Biochemistry, and Behavior. 2012; 102 (1): 95–100.
57. M. S. Kramer,N.Cutler, J. Feighner et al., “Distinctmechanism for antidepressant activity by blockade of central substance P receptors,”Science , 1998; 281, (5383),1640–5.
58. M. Mu˜noz, M. Berger, M. Rosso, A. Gonzalez-Ortega, A. Carranza, and R. Cove˜nas, “Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts,” International Journal of Oncology , 2014; 44, (1),137–46.
59. M. Munoz, A. Gonzalez-Ortega, M. V. Salinas-Martin et al., “The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer,” International Journal of Oncology , 2014; 45,1658–72.
60. M. Berger, O. Neth, M. Ilmer et al., “Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo,” Journal of Hepatology , 2014 60, (5),985–94.
61. M. Mu˜noz and M. Rosso, “The NK-1 receptor antagonist aprepitant as a broad-spectrum antitumor drug,” Investigational NewDrugs , 2010, 28, (2), pp. 187–93.
62. Onori L, Aggio A, Taddei G, Tonini M: Contribution of NK (2) tachykinin receptors to propulsion in the rabbit distal colon. Am J Physiol 2000; (278): G137–47.
63. Fioramonti J, Gaultier E, Toulouse M, Sanger GJ, Bueno L: Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action. Neurogastroenterol Motil 2003; 15: 363–9.
64. Shafton AD, Bogeski G, Kitchener PD, Lewis VA, Sanger GJ, Furness JB: Effects of the peripherally acting NK receptor antagonist, SB-235375, on intestinal and somatic nociceptive responses and on intestinal motility in anaesthetized rats. Neurogastroenterol Motil 2004; 16: 223–31.
65. Hwang L, Leichter R, Okamoto A, Payan D, Collins SM, Bunnett NW: Downregulation of
neutral endopeptidase (EC 3.4.24.11) in the inflamed rat intestine. Am J Physiol 1993; 264: G735–43.
66. Sturiale S, Barbara G, Qiu B, Figini M, Geppetti P, Gerard N et al: Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. Proc Natl Acad Sci USA 1999; 96:11653–8.
67. Barbara G, De Giorgio R, Stanghellini V, Corinaldesi R, Cremon C, Gerard N et al: Neutral endopeptidase (EC 3.4.24.11) downregulates the onset of intestinal inflammation in the nematode infected mouse. Gut 2003; 52: 1457–64.
68. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al: GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology. 2011, 64 (4): 401-6.
69. Joos GF, Pauwels RA: Tachykinin receptor antagonists: potential in airways diseases. Current Opinion in Pharmacology. 2001, 1 (3): 235-41.
70. Schuiling M, Zuidhof AB, Zaagsma J, Meurs H: Involvement of tachykinin NK1 receptor in the development of allergen-induced airway hyperreactivity and airway inflammation in conscious, unrestrained guinea pigs. Am J Respir Crit Care Med. 1999, 159 (2): 423-30.
71. Tebas P, Tuluc F, Barrett JS, Wagner W, Kim D, Zhao H et al. A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. PLoS One. 2011;6(9): e24180.
72. Roberts, Claire; Inamdar, Amir; Koch, Annelize; Kitchiner, Pauline; Dewit, Odile; Merlo-Pich, Emilio et al.  A Randomized, Controlled Study Comparing the Effects of Vestipitant or Vestipitant and Paroxetine Combination in Subjects with Tinnitus, Otology & Neurotology: 2011;32;(5) 721-7
73. Mathew SJ, Vythilingam M, Murrough JW, Zarate CA Jr, Feder A, Luckenbaugh DA,et al. A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol. 2011 Mar;21(3):221-9.
74. Tack J, Schumacher K, Tonini G, Scartoni S, Capriati A, Maggi CA; Iris-2 investigators. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS. Gut. 2017; 66(8):1403-13.
75. Tauscher J, Kielbasa W, Iyengar S, Vandenhende F, Peng X, Mozley D et al. Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur Neuropsychopharmacol. 2010 Feb;20(2):80-7.
76.  ”GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa”  (PDF) . London: EMEA. 13 October 2009. Archived from the original (PDF)  on 15 October 2009. Retrieved 21 December 2009
80. Saffroy M, Torrens Y, Glowinski J, et al. Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience 2003; 116:761-73
81. Le Fur G. In: Sanofi-Synthe´labo Information Meeting, February 16, 2004, 53-6
82. Hopkins CR. ACS chemical neuroscience molecule spotlight on Saredutant. ACS Chemical Neuroscience. 2010 Oct;1(10):653-4.
83. Rayes, N., Bowen, D.J., Coffin, T. et al.  MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing. BMC Cancer  2019; 19 648.
84. Almeida TA, Rojo J, Nieto PM, et al. Tachykinin and tachykinin receptors: structure and activity relationships. Curr Med Chem 2004; 11:2045-81
85. Rigby M, O’Donnell R, Rupniak NM. Species differences in tachykinin receptor
distribution: further evidence that the substance P (NK1) receptor predominates
in human brain. J Comp Neurol 2005; 490:335-53
86. Couture R, Toma N, Barbot L. SR142801 behaves as a tachykinin NK-3 receptor
agonist on a spinal nociceptive reflex in the rat. Life Sci 2000; 66:51-65
87. Meltzer HY, Arvanitis L, Bauer D, et al. A placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorders. Am J Psychiat 2004; 161:975-84
88. GSK R&D Day 2003. Psychiatry update
89. Gorelik, G., Carbini, L. A. & Scicli, A. G. Angiotensin 1–7 induces bradykinin- mediated relaxation in porcine coronary artery.J. Pharmacol. Exp. Ther. 1998; 286,403–10.
90. Bossi, F. et al. Platelet- activating factor and kinindependent vascular leakage as a novel functional activity of the soluble terminal complement complex. J. Immunol. 2004; 173, 6921–7.
91. Turner DJ, Guota K, Yang XX, Martin JG. Bradykinin-induced airway constriction in guinea-pigs: role of leukotriene D4. Pulm Pharmacol Ther 2000; 13:181–188.
92. Arakawa, M., Majima, M., Nagai, K. et al.  Role of tachykinins in enhancement of bradykinin-induced bronchoconstriction by captopril. Inflamm Res 1996; 45,  75–82.